Amy Baxter
Staff ReporterAmy Baxter is a staff reporter for PharmaVoice. Before joining the team, she served as an editor and reporter in the B2B healthcare space for eight years at Health Exec and Home Health Care News. She also covered the retail industry as editor of Retail Leader, and hosted an Hermes award-winning weekly podcast and video interview series, Trend Talk, featuring industry executives and experts. A lifelong sailor, Amy has taken her media skills on the water to cover regattas and sailing events across the country. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Race to Mackinac Island. She is based in Florida.
97 articles by Amy Baxter
-
Lilly, Novo expand DTC reach of obesity meds after compound win
March 24, 2025 -
Vaccine makers face mRNA backlash as states seek further restrictions
March 19, 2025 -
Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
March 17, 2025 -
IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?
March 12, 2025 -
The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
March 11, 2025 -
How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?
March 7, 2025 -
How pharma CEO pay shifted for these 4 companies last year
March 3, 2025 -
Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms
Feb. 24, 2025 -
Challenges mount for vaccine makers
Feb. 19, 2025 -
The kids are alright: How pharma can make inroads with Gen Z
Feb. 12, 2025 -
Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments
Feb. 10, 2025 -
RFK Jr. will face these critical tests if confirmed as head of the HHS
Feb. 5, 2025 -
Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge
Jan. 31, 2025 -
A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?
Jan. 29, 2025 -
An ALS treatment wave is approaching, and this biotech CEO is ready to surf
Jan. 27, 2025 -
Innovate or perish: Industry’s evolution leaves little room for me-too approaches
Jan. 21, 2025 -
What to expect in the sequel to Medicare’s drug price negotiation program
Jan. 15, 2025 -
FDA ‘stuck to its corner’ with AI draft guidance, leaving plenty of questions unanswered
Jan. 13, 2025 -
3 trial readouts that could shake up the obesity market this year
Jan. 8, 2025 -
PBMs have evaded lawmakers’ reform attempts so far. Could 2025 turn the tide?
Jan. 6, 2025 -
Big Pharma’s new DTC play: partnering with digital health providers
Dec. 18, 2024 -
Oncology, obesity and more: Where pharma R&D is headed in 2025
Dec. 16, 2024 -
GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?
Dec. 11, 2024 -
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
Dec. 9, 2024 -
With Makary set to face FDA commissioner hearings, how deep do his industry ties run?
Dec. 4, 2024